Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

被引：1
|
作者：
Ebia, Matthew I. [1 ]
Hitchins, Megan P. [2 ]
Hendifar, Andrew E. [1 ,3 ,4 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[3] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
[4] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, 8700 Beverly Blvd,Suite 1042AC, Los Angeles, CA 90048 USA
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2023年 / 14卷 / 02期
关键词：
Pancreatic ductal adenocarcinoma (PDAC); DNA deficient mismatch repair (DNA dMMR); microsatellite instability (MSI); Lynch syndrome; immunotherapy; CANCER;
D O I：
10.21037/jgo-23-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：1175 / 1177
页数：3
相关论文
共 50 条
  • [31] Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
    Jia-qiao Fan
    Meng-Fei Wang
    Hai-Long Chen
    Dong Shang
    Jugal K. Das
    Jianxun Song
    Molecular Cancer, 19
  • [32] Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
    Li, Yan
    Hong, Young K.
    Wang, Xingtong
    Pandit, Harshul
    Zheng, Qianqian
    Yu, Youxi
    Shi, Xiaoju
    Chen, Yujia
    Tan, Min
    Pulliam, Zachary
    Bhutiani, Neal
    Lin, Andrew
    Badach, Jeremy
    Zhang, Ping
    Martin, Robert C. G.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (12)
  • [33] Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
    Caitlyn Smith
    Wei Zheng
    Jixin Dong
    Yaohong Wang
    Jinping Lai
    Xiuli Liu
    Feng Yin
    World Journal of Gastroenterology, 2022, 28 (27) : 3297 - 3313
  • [34] Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
    Bailey, Peter
    Chang, David K.
    Forget, Marie-Andree
    San Lucas, Francis A.
    Alvarez, Hector A.
    Haymaker, Cara
    Chattopadhyay, Chandrani
    Kim, Sun-Hee
    Ekmekcioglu, Suhendan
    Grimm, Elizabeth A.
    Biankin, Andrew V.
    Hwu, Patrick
    Maitra, Anirban
    Roszik, Jason
    SCIENTIFIC REPORTS, 2016, 6
  • [35] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
    Paniccia, Alessandro
    Merkow, Justin
    Edil, Barish H.
    Zhu, Yuwen
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (04) : 376 - 391
  • [36] Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy
    Luong, Tha
    Golivi, Yuvasri
    Nagaraju, Ganji Purnachandra
    El-Rayes, Bassel F.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 68 : 107 - 115
  • [37] Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
    Peter Bailey
    David K. Chang
    Marie-Andrée Forget
    Francis A. San Lucas
    Hector A. Alvarez
    Cara Haymaker
    Chandrani Chattopadhyay
    Sun-Hee Kim
    Suhendan Ekmekcioglu
    Elizabeth A. Grimm
    Andrew V. Biankin
    Patrick Hwu
    Anirban Maitra
    Jason Roszik
    Scientific Reports, 6
  • [38] Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
    Su, Alan
    Pedraza, Rodrigo
    Kennecke, Hagen
    CURRENT ONCOLOGY, 2023, 30 (04) : 3672 - 3683
  • [39] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [40] Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
    Schweizer, Michael T.
    Cheng, Heather H.
    Tretiakova, Maria S.
    Vakar-Lopez, Funda
    Klemfuss, Nola
    Konnick, Eric Q.
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Yu, Evan Y.
    Montgomery, Bruce
    True, Lawrence D.
    Pritchard, Colin C.
    ONCOTARGET, 2016, 7 (50) : 82504 - 82510
12345